ArticleOncology letters2015

Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma.

Feng Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.